Vinblastine
"Vinblastine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
| Descriptor ID |
D014747
|
| MeSH Number(s) |
D03.132.436.681.827.650 D03.438.473.402.681.827.650
|
| Concept/Terms |
Velban- Velban
- Vinblastina Lilly
- Velbe
- EG Labo Brand of Vinblastine Sulfate
- Lilly Brand of Vinblastine Sulfate
cellblastin- cellblastin
- cell pharm Brand of Vinblastine Sulfate
Lemblastine- Lemblastine
- Lemery Brand of Vinblastine Sulfate
|
Below are MeSH descriptors whose meaning is more general than "Vinblastine".
Below are MeSH descriptors whose meaning is more specific than "Vinblastine".
This graph shows the total number of publications written about "Vinblastine" by people in UAMS Profiles by year, and whether "Vinblastine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2008 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2001 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 1994 | 1 | 0 | 1 |
| 1991 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vinblastine" by people in Profiles over the past ten years.
-
Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Rachmilewitz Minei T, Harats D, Wall JA, Foxall ME, Penson RT. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol. 2020 06; 157(3):578-584.
-
Ayesh Haj Yousef MH, Eyadeh A, Rawashdeh RA, Khasawneh R, Saleh JA, Jibreel MJ. Vinblastine-induced posterior reversible encephalopathy syndrome. J Oncol Pharm Pract. 2019 Dec; 25(8):2019-2022.